Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy

NCT00722930 is registered in ClinicalTrials.gov with Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas as lead sponsor.

NCT NCT00722930
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00722930 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Consolidation Treatment With Y90-Ibritumomab Tiuxetan In Patients With High-Risk Follicular Lymphoma With Either Partial Or Complete Response To R-Chop Induction Chemotherapy
Lead sponsor
Grupo Oncológico para el Tratamiento y el Estudio de los Linfomas
Phase
Phase 2
Overall status
Unknown status
Start date
April 30, 2008
Completion date
April 30, 2013
Enrollment
38 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma